RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiniksa Pharmaceuticals Stock

Kiniksa Pharmaceuticals Employees 2024

Kiniksa Pharmaceuticals Employees

168

Ticker

KNSA

ISIN

BMG5269C1010

WKN

A2JMVJ

In 2024, Kiniksa Pharmaceuticals employed 168 people, a 0% change from the 168 number of employees in the previous year.

Kiniksa Pharmaceuticals Aktienanalyse

What does Kiniksa Pharmaceuticals do?

Kiniksa Pharmaceuticals Ltd is a US biotech company founded in 2015 and headquartered in Lexington, Massachusetts. The company specializes in the development and commercialization of therapies for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals' business model is based on collaboration with leading scientists and clinicians to develop innovative solutions for patients with complex clinical needs. The company's products focus on various inflammatory diseases and have multiple candidates in the pipeline for different indications in clinical development. Kiniksa Pharmaceuticals has also focused on developing therapies for rare diseases. A key feature of the company is its high-throughput platform, which allows for the identification and validation of potential therapeutics in a short amount of time. Kiniksa Pharmaceuticals was founded in 2015 by former executives from Biogen and Vertex Pharmaceuticals who had extensive experience in the discovery and development of drugs for chronic inflammatory diseases. The company quickly received an initial funding of $60 million and has since sought additional financing to expand its technology platform and scientific expertise. Kiniksa Pharmaceuticals consists of several divisions, including the development division, which is responsible for the clinical development of therapeutics for rare and chronic inflammatory diseases. Another important division is product development, which specializes in the identification and validation of candidates for potential therapeutics. This includes the identification of biomarkers that can serve as indicators of drug effectiveness. Kiniksa Pharmaceuticals also has a marketing division responsible for the commercialization of already approved products. The products of Kiniksa Pharmaceuticals focus on the treatment of inflammatory diseases. One of the key candidates currently in clinical development is KPL-716, a potential monoclonal antibody that can be used for multiple indications, including cutaneous T-cell lymphoma and chronic obstructive asthma. Another important potential is the candidate Mavrilimumab, a potential monoclonal antibody that can be used for the treatment of giant cell arteritis and polymyalgia rheumatica. Other key candidates include KPL-404, a potential monoclonal antibody that can be used for the treatment of ulcerative colitis. Overall, Kiniksa Pharmaceuticals has a promising future by focusing on innovative products for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Kiniksa Pharmaceuticals's Employee Base

Kiniksa Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Kiniksa Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Kiniksa Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Kiniksa Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Kiniksa Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Kiniksa Pharmaceuticals stock

How many employees does Kiniksa Pharmaceuticals have this year?

Kiniksa Pharmaceuticals has 168 undefined employees this year.

How many employees did Kiniksa Pharmaceuticals have compared to the previous year?

Compared to the previous year, Kiniksa Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Kiniksa Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Kiniksa Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Kiniksa Pharmaceuticals?

The number of employees can also have an impact on investors of Kiniksa Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Kiniksa Pharmaceuticals affect the company?

An increase in equity of Kiniksa Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Kiniksa Pharmaceuticals's equity affect the company?

A reduction in equity of Kiniksa Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Kiniksa Pharmaceuticals?

Some factors that can influence the equity of Kiniksa Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Kiniksa Pharmaceuticals so important for investors?

The equity of Kiniksa Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Kiniksa Pharmaceuticals influence the company?

The number of employees at Kiniksa Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Kiniksa Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Kiniksa Pharmaceuticals has changed by 0.

How many employees does Kiniksa Pharmaceuticals currently have?

Kiniksa Pharmaceuticals currently has 168 undefined employees.

Why is the number of employees important for investors of Kiniksa Pharmaceuticals?

The number of employees is important for investors of Kiniksa Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Kiniksa Pharmaceuticals take to change the number of employees?

To change the number of employees, Kiniksa Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Kiniksa Pharmaceuticals pay?

Over the past 12 months, Kiniksa Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiniksa Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Kiniksa Pharmaceuticals?

The current dividend yield of Kiniksa Pharmaceuticals is .

When does Kiniksa Pharmaceuticals pay dividends?

Kiniksa Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Kiniksa Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiniksa Pharmaceuticals located?

Kiniksa Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiniksa Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiniksa Pharmaceuticals from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.

When did Kiniksa Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/31/2024.

What was the dividend of Kiniksa Pharmaceuticals in the year 2023?

In the year 2023, Kiniksa Pharmaceuticals distributed 0 USD as dividends.

In which currency does Kiniksa Pharmaceuticals pay out the dividend?

The dividends of Kiniksa Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kiniksa Pharmaceuticals

Our stock analysis for Kiniksa Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiniksa Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.